Back to News
Market Impact: 0.35
Milestone Wins NMPA Approval For Etripamil Nasal Spray In PSVT
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationCompany Fundamentals
Milestone Pharmaceuticals (MIST) said China’s NMPA approved CARDAMYST (etripamil) nasal spray for treating paroxysmal supraventricular tachycardia. This regulatory approval is a key commercialization milestone and should improve the company’s prospects for product uptake in China.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
MIST0.75
More News
- Bending Spoons wants to revive software castoffs. Berkshire is backing the plan
- AI rapidly improving, could vastly boost U.S. GDP, Anthropic's Clark tells policymakers
- ‘How many canaries have we killed in the coal mine?’ — Wall Street debates if the latest AI bubble warnings are another head fake or the real thing
- Tunisia’s economic crisis deepens as the promise of a better life fades
- States sue OpenAI, saying it gives life to ‘cyberhacking agents’ while ChatGPT hurts children and deceives adults
- Mark Carney makes closing argument to Alberta against path to independence from Canada: outsiders ‘are working to break us so they can own us. Never’